SCHEMBL7970930

SCHEMBL7970930

CNC(=O)c1ccccc1CCc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.69
ADRB2 P07550 1/20 0.69
HTT P42858 1/20 0.66
LMNA P02545 3/20 0.64
L3MBTL1 Q9Y468 2/20 0.64
KDM4E B2RXH2 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
MAPT P10636 1/20 0.61
GAA P10253 2/20 0.54
HPGD P15428 1/20 0.54
KMT2A Q03164 1/20 0.51
KDR P35968 1/20 0.50
BRD4 O60885 1/20 0.50
BRD2 P25440 1/20 0.50
BRD3 Q15059 1/20 0.50
BRDT Q58F21 1/20 0.50
SCN1A P35498 1/20 0.49
SCN2A Q99250 1/20 0.49
SCN3A Q9NY46 1/20 0.49
TSHR P16473 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11783350 0.87 ALDH1A1 (0.57) ALDH1A1ADRB2HTTLMNAL3MBTL1
SCHEMBL3109472 0.86 CAPN1 (0.57) ALDH1A1ADRB2HTTLMNAL3MBTL1
SCHEMBL974386 0.84 ALDH1A1 (0.71) ALDH1A1ADRB2HTTLMNAL3MBTL1
SCHEMBL22994602 0.84 ALDH1A1 (0.71) ALDH1A1ADRB2HTTLMNAL3MBTL1
SCHEMBL21192538 0.82 GAA (0.56) ALDH1A1ADRB2HTTLMNAL3MBTL1
SCHEMBL13705878 0.82 GAA (0.52) ALDH1A1ADRB2HTTLMNAL3MBTL1
SCHEMBL11743421 0.82 GAA (0.52) ALDH1A1ADRB2HTTLMNAL3MBTL1
SCHEMBL8338794 0.81 GAA (0.55) ALDH1A1ADRB2HTTLMNAL3MBTL1
SCHEMBL31497733 0.80 LMNA (0.65) ALDH1A1ADRB2HTTLMNAL3MBTL1
SCHEMBL9806384 0.80 LMNA (0.65) ALDH1A1ADRB2HTTLMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190040036-A1 HYPERVALENT IODINE CF2CF2X REAGENTS AND THEIR USE ETH ZURICH (CH) 2019-02-07 US disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
EP-2298747-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2011-03-23 EP disclosed
WO-2010001946-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF アステラス製薬株式会社 (JP) 2010-01-07 WO disclosed
CN-1856476-A Isoquinolinone potassium channel inhibitors MERCK & CO INC (US) 2006-11-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF HSD11B1, HSD11B2, HSD3B1 ALDH1A1 359/4885ADRB2 615/4885HTT 370/4885
US-20190040036-A1 HYPERVALENT IODINE CF2CF2X REAGENTS AND THEIR USE TPO, FANCF, FANCI ALDH1A1 4122/4885ADRB2 3044/4885HTT 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.